The Hong Kong Diabetes Biobank
Launched by CHINESE UNIVERSITY OF HONG KONG · Mar 7, 2022
Trial Information
Current as of April 26, 2025
Recruiting
Keywords
ClinConnect Summary
The Hong Kong Diabetes Biobank (HKDB) is a research project aimed at understanding diabetes better, especially its complications like kidney disease and heart problems. With diabetes affecting over 110 million people in China, the goal of this study is to find out how genetic factors and other biological markers can help predict who might develop serious complications from diabetes. By collecting detailed health information and blood samples from individuals with diabetes at centers across Hong Kong, researchers hope to discover new ways to identify high-risk patients early and improve treatment options.
To participate in this trial, you need to have a diagnosis of diabetes and be able to give written consent. Unfortunately, if you cannot provide consent, you won’t be eligible to join. If you decide to participate, you can expect to undergo a thorough health assessment and provide information about your medical history. You will be followed over time to see how your diabetes progresses and any related health issues that arise. This study aims not only to advance our understanding of diabetes but also to contribute to better healthcare strategies for managing this condition in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • subjects with known diabetes
- Exclusion Criteria:
- • subjects not capable of giving written informed consent
About Chinese University Of Hong Kong
The Chinese University of Hong Kong (CUHK) is a prestigious research institution renowned for its commitment to advancing medical science and improving healthcare outcomes. As a clinical trial sponsor, CUHK leverages its extensive academic resources and interdisciplinary expertise to conduct innovative research that addresses critical health challenges. The university fosters collaboration among leading researchers, healthcare professionals, and industry partners, ensuring rigorous study design and implementation. CUHK is dedicated to upholding the highest ethical standards in clinical research, with a focus on translating findings into tangible benefits for patients and the broader community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Shatin, , Hong Kong
Patients applied
Trial Officials
Ronald C Ma, FRCP
Principal Investigator
Department of Medicine and Therapeutics, The Chinese University of Hong Kong
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials